FORT LAUDERDALE, Fla., April 26, 2016 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced the signing of a five-year, multi-million dollar agreement with CROMSOURCE, a leading contract research organization (CRO), headquartered in Verona, Italy, with offices throughout Europe and North America. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five-year term in trials spanning all clinical phases and numerous therapeutic areas.
Dr. Oriana Zerbini, founder and CEO of CROMSOURCE stated, “As the global clinical trial services market continues to be increasingly competitive, we want to provide our clients with the most effective technologic tools to ensure their trials are completed efficiently and with the highest level of quality possible. We believe that TrialMaster provides that opportunity, and are pleased to have established this long-term relationship with OmniComm.”
TrialMaster was selected by CROMSOURCE for its inherent flexibility, scalability, data quality, and broad capabilities. CROMSOURCE selected TrialMaster’s rich and versatile toolset that makes study builds easier to learn and easier to work with, enabling faster study start-up times when compared to other competing technologies.
Additional capabilities that were critical to their decision include:
- TrialMaster Custom Data Export Utility to create CDISC SDTM submission ready data;
- Ad hoc reporting to create and share dashboards, reports, and analysis;
- Risk-based monitoring to centrally monitor key risk indicators (KRIs) and identify emerging risks across sites and subjects; and,
- Support for adverse events, especially the ability to generate E2B exports with TrialMaster SafetyLink, a requirement being requested more frequently by CROMSOURCE clients.
“It is an honor to be chosen by a CRO that is so well known for delivering quality and meeting stringent timelines,” said Stephen Johnson, president & COO of OmniComm. “TrialMaster’s intuitive usability coupled with extensive time-saving features is designed to reduce the time for set-up and promote efficiencies throughout the data collection process. We look forward to working with CROMSOURCE and their clients over the next five years!”
CROMSOURCE is an ISO-certified, international contract research organization providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries. Specializing in clinical development and staffing solutions they offer a flexible approach to ensure their clients’ unique needs are supported. CROMSOURCE is unparalleled in offering an end-to-end guarantee covering trial timelines, enrollment, and contract price. This guarantees our clients that their trials are delivered on-time and within the contract price with no CRO initiated change orders. CROMSOURCE operates offices across all regions of Europe and North America. For more information, visit http://www.cromsource.com.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Dennis Constantinou OmniComm Systems, Inc. +1.954.473.1254 email@example.com
Source:OmniComm Systems Inc.